We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+23.6%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$147M
AUM Growth
-$44.4M
(-23%)
Cap. Flow
-$65.4M
Cap. Flow
% of AUM
-44.37%
Top 10 Holdings %
Top 10 Hldgs %
60.34%
Holding
94
New
22
Increased
8
Reduced
10
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
+$9.68M |
| 2 |
CPRX
Catalyst Pharmaceutical
CPRX
|
+$5.26M |
| 3 |
Savara
SVRA
|
+$5.11M |
| 4 |
Vera Therapeutics
VERA
|
+$3.57M |
| 5 |
Insmed
INSM
|
+$3.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
+$12.3M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
+$11.5M |
| 3 |
Structure Therapeutics
GPCR
|
+$7.82M |
| 4 |
Biohaven
BHVN
|
+$7.46M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$6.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.95% |
| 2 | Communication Services | 0.3% |
| 3 | Consumer Staples | 0.05% |
| 4 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Xenon Pharmaceuticals
XENE
$6.28B
| $13.4M | 9.08% |
290,535
+62,535
| +27% | +$2.21M |
|
|
ALIM
2
DELISTED
Alimera Sciences
ALIM
| $11.5M | 7.8% |
2,660,000
-274,108
| -9% | -$926K |
|
3
Axsome Therapeutics
AXSM
$12.1B
| $11M | 7.46% |
138,000
+46,000
| +50% | +$3.08M |
|
|
4
Alpha Architect 1-3 Month Box ETF
BOXX
$13.1B
| $9.75M | 6.62% |
+92,700
| New | +$9.68M |
|
|
5
Vera Therapeutics
VERA
$2.39B
| $9.46M | 6.42% |
615,000
+281,319
| +84% | +$3.57M |
|
6
Xtant Medical Holdings
XTNT
$59.7M
| $9.07M | 6.16% |
8,027,593
-906,769
| -10% | -$1.07M |
|
|
CPRX
7
DELISTED
Catalyst Pharmaceutical
CPRX
| $6.47M | 4.39% |
+385,000
| New | +$5.26M |
|
|
8
Savara
SVRA
$1.09B
| $6.27M | 4.25% |
+1,333,000
| New | +$5.11M |
|
9
Oric Pharmaceuticals
ORIC
$1.23B
| $6.22M | 4.22% |
676,000
+257,294
| +61% | +$1.86M |
|
10
Olema Pharmaceuticals
OLMA
$1.01B
| $5.8M | 3.94% |
413,607
+78,607
| +23% | +$1.06M |
|
|
ATXS
11
DELISTED
Astria Therapeutics
ATXS
| $5.61M | 3.81% |
730,000
-617,088
| -46% | -$3.41M |
|
|
ITCI
12
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.09M | 3.45% |
71,000
+43,000
| +154% | +$2.47M |
|
13
ADMA Biologics
ADMA
$2.04B
| $4.95M | 3.36% |
1,095,000
-1,628,011
| -60% | -$6.02M |
|
|
SLNO
14
DELISTED
Soleno Therapeutics
SLNO
| $4.22M | 2.87% |
104,909
+57,828
| +123% | +$1.65M |
|
|
15
Insmed
INSM
$22.6B
| $3.72M | 2.52% |
+120,000
| New | +$3.11M |
|
16
Immunovant
IMVT
$7.99B
| $3.37M | 2.29% |
+80,000
| New | +$2.94M |
|
17
Ascendis Pharma A/S
ASND
$16.7B
| $3.15M | 2.14% |
+25,000
| New | +$2.49M |
|
|
CBAY
18
DELISTED
Cymabay Therapeutics
CBAY
| $2.62M | 1.78% |
111,000
-689,000
| -86% | -$12.3M |
|
19
Sagimet Biosciences
SGMT
$449M
| $2.53M | 1.72% |
483,181
| – | – |
|
20
Crinetics Pharmaceuticals
CRNX
$8.88B
| $2.31M | 1.57% |
65,000
-197,000
| -75% | -$6.04M |
|
|
MRNS
21
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $2.17M | 1.48% |
200,000
+74,967
| +60% | +$562K |
|
|
NVNO
22
enVVeno Medical
NVNO
$6.94M
| $1.77M | 1.2% |
+9,842
| New | +$1.57M |
|
|
23
Amylyx Pharmaceuticals
AMLX
$2.17B
| $1.76M | 1.19% |
119,526
-415,174
| -78% | -$6.36M |
|
24
Cytokinetics
CYTK
$10.8B
| $1.67M | 1.13% |
+20,000
| New | +$724K |
|
|
ALPN
25
DELISTED
Alpine Immune Sciences Inc
ALPN
| $1.5M | 1.02% |
+78,723
| New | +$1.09M |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Altium Capital Management held 94 positions worth $147M, down 23% from $192M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Altium Capital Management withdrew a net $65.4M in Q4 2023, closing 28 positions and reducing 10 holdings. Its most notable exit was Immunogen Inc, an estimated $11.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Communication Services and Consumer Staples.
Against the trend, Altium Capital Management opened a new position in Alpha Architect 1-3 Month Box ETF worth $9.75M.
- Altium Capital Management's largest Q4 2023 buy was Alpha Architect 1-3 Month Box ETF: 92,700 shares worth $9.75M.
- Altium Capital Management added most to Vera Therapeutics in Q4 2023, an estimated $3.57M increase.
- Altium Capital Management's biggest Q4 2023 reduction was Cymabay Therapeutics, cutting an estimated $12.3M.
- Altium Capital Management fully exited Immunogen Inc in Q4 2023, selling an estimated $11.5M.
- Altium Capital Management's ten largest holdings make up 60% of its $147M portfolio in Q4 2023.
- Altium Capital Management opened 22 new positions and closed 28 in Q4 2023.
- Altium Capital Management's portfolio value fell 23% quarter-over-quarter to $147M.
Based on Altium Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.